New PET tracer could reveal hidden cancer response

NCT ID NCT06414902

Recruiting now Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a special PET scan using a radioactive tracer called 18F-AraG can find tumors in people with esophageal cancer and predict how well they respond to chemoradiation. About 60 adults with untreated, locally advanced esophageal cancer will receive the tracer and be scanned. The main goal is to check safety, but researchers also hope to see if the scan can serve as a biomarker for treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-AraG (a radioactive tracer given by IV)
What this could lead to: If successful, this could give doctors a new way to see if chemoradiation is working in esophageal cancer patients, potentially guiding better treatment decisions.
What could go wrong: This is a very early Phase 1 study with only 60 people. The main goal is safety, not yet proving the scan predicts response. It may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.